Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - poliovirus vaccine live oral streptomycin polymyxin b neomycin - 5 milligram

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - poliovirus, inactivated, type, mahoney strain, mef, saukett strain - suspension for injection - poliovirus (inactivated) type 1 (mahoney strain) 8 dagu poliovirus (inactivated) type 2 (mef-1 strain) 40 dagu poliovirus (inactivated) type 3 (saukett strain) 40 dagu - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - poliovirus, inactivated, type, mahoney strain, mef, saukett strain - suspension for injection - poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - poliovirus vaccine live oral polymyxin b neomycin - 2 millilitre

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monobasic potassium phosphate; potassium chloride; hydrolysed gelatin; sodium chloride; dibasic sodium phosphate; urea; sucrose; monosodium glutamate monohydrate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - poliovirus type 1 antigen (formaldehyde inactivated) 40 [d'ag'u] in 0.5 ml - ipol vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. (28) it is recommended that all infants (as young as 6 weeks of age), unimmunized children, and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis. (29) following the eradication of poliomyelitis caused by wild poliovirus from the western hemisphere (including north and south america) (30), an ipv-only schedule was recommended to eliminate vapp. (7) all children should receive four doses of ipv at ages 2, 4, 6 to 18 months, and 4 to 6 years. opv is no longer available in the us and is not recommended for routine immunization. (7) previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with opv are not contraindications to completing the primary series of immunization with ipol vaccine. children of all ages should have their immuni

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; urea; sodium chloride; potassium chloride; sucrose; hydrolysed gelatin; monobasic potassium phosphate; dibasic sodium phosphate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - diluent, not applicable - excipient ingredients: water for injections - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 17 dagu; poliovirus, quantity: 20 dagu; poliovirus, quantity: 5 dagu - injection, suspension - excipient ingredients: sodium hydroxide; hydrochloric acid; formaldehyde solution; phenoxyethanol; glucose monohydrate; purified water; polysorbate 80; ascorbic acid; sodium chloride; aminobenzoic acid; adenosine phosphate; dl-alpha-tocopheryl phosphate disodium; magnesium sulfate; monobasic potassium phosphate; deoxyribose; calcium chloride dihydrate; iron trinitrate; potassium chloride; magnesium sulfate heptahydrate; potassium nitrate; sodium selenite; monobasic sodium phosphate; dibasic sodium phosphate heptahydrate; adenine sulfate; adenosine triphosphate disodium; cholesterol; glutathione; guanine hydrochloride; hypoxanthine; phenolsulfonphthalein; ribose; sodium acetate; thymine; uracil; xanthine; sodium pyruvate; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; hydroxyproline; isoleucine; asparagine; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. ipol should be offered to patients who have refused opv or in whom opv is contraindicated. ipol is also indicated for: 1) the primary vaccination of immunocompromised individuals of all ages, and household contacts of such individuals (when vaccination is indicated); (2) unvaccinated or inadequately vaccinated(*) adults, particularly if at increased risk of exposure to live polio virus, including: - travellers to areas or countries where poliomyelitis is epidemic or endemic: - laboratory workers handling specimens which may contain polio virus; - health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who may not have completed a primary series of vaccination or not received a booster dose since infancy. idications as at 9 june 2003: ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommen

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 3 µg pertussis toxoid 20 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 20 µg fimbriae types 2 and 3 5 µg haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines